AN2 Therapeutics (NASDAQ: ANTX) officer receives major new equity grants

Rhea-AI Filing Summary

Eizen Joshua M reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics officer Joshua M. Eizen reported new equity awards. He was granted a stock option covering 100,000 shares, which vests in equal monthly installments over four years from January 1, 2026, subject to continued service. He also received 50,000 restricted stock units that vest 25% annually over four years from January 1, 2026, on the same service condition. Following these awards, he directly owns 207,499 shares of common stock, which includes prior RSU grants and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Eizen Joshua M

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	100,000	$0.00	--
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 100,000 shares (Direct); Common Stock — 207,499 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/23/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eizen Joshua M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		50,000(1)	A	$0	207,499(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.04	02/20/2026		A		100,000		(4)	02/19/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

2. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.

4. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Remarks:

Chief Operating Officer and Chief Legal Officer

	/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Joshua M. Eizen receive from AN2 Therapeutics (ANTX)?

Joshua M. Eizen received two equity awards: a stock option for 100,000 shares and 50,000 restricted stock units. Both were granted on February 20, 2026, and are tied to his continued service with AN2 Therapeutics over multi-year vesting schedules.

How do the new stock option awards for AN2 Therapeutics (ANTX) officer vest?

The stock option covering 100,000 shares vests in 48 equal monthly installments over four years starting January 1, 2026. Each month, 1/48th of the underlying shares becomes exercisable, provided Joshua M. Eizen remains in continuous service through each monthly vesting date.

What is the vesting schedule for the 50,000 restricted stock units at AN2 Therapeutics (ANTX)?

The 50,000 restricted stock units vest 25% each year over four years beginning January 1, 2026. One-quarter of the units vests annually, and each installment requires Joshua M. Eizen to remain in continuous service through the applicable vesting date.

How many AN2 Therapeutics (ANTX) shares does Joshua M. Eizen own after these transactions?

After the reported grants, Joshua M. Eizen directly holds 207,499 shares of AN2 Therapeutics common stock. This total includes previously awarded restricted stock units and an additional 5,000 shares acquired under the 2022 Employee Stock Purchase Plan on March 31, 2025.

Are Joshua M. Eizen’s AN2 Therapeutics (ANTX) equity awards subject to any conditions?

Yes. Both the 100,000-share stock option and the 50,000 restricted stock units vest only if Joshua M. Eizen maintains continuous service. Each vesting installment, whether monthly for options or annually for RSUs, depends on him remaining with AN2 Therapeutics through the specific vesting dates.

What prior restricted stock units does the AN2 Therapeutics (ANTX) Form 4 reference?

The disclosure notes existing RSU balances of 30,000, 60,000, 31,500, and 58,500 units, each with its own multi-year vesting schedule beginning between January 1, 2024, and January 1, 2025. Every tranche requires Joshua M. Eizen’s continuous service through the respective vesting dates.